Clinical Trials Logo

Cervix Cancer clinical trials

View clinical trials related to Cervix Cancer.

Filter by:

NCT ID: NCT04514692 Recruiting - Endometrial Cancer Clinical Trials

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging

Start date: February 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor. Growth factors are proteins made in the body. G-CSF is a type of growth factor that makes the bone marrow produce white blood cells to reduce the risk of infection after some types of cancer treatment.

NCT ID: NCT04405349 Completed - Cervical Cancer Clinical Trials

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This phase IIa study is designed to evaluate the safety and efficacy of multiple dosing with VB10.16 immunotherapy in combination with atezolizumab in patients with advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care.

NCT ID: NCT04357873 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

PEVOsq
Start date: October 28, 2020
Phase: Phase 2
Study type: Interventional

Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)

NCT ID: NCT04334239 Completed - Breast Cancer Clinical Trials

Effectiveness of Care in Certified Cancer Centres in Germany

WiZen
Start date: May 1, 2017
Phase:
Study type: Observational

Assessment of the effectiveness of care in certified cancer centres for eight cancer entities via a retrospective cohort study based on secondary data from statutory health insurance funds and population-based clinical cancer registries.

NCT ID: NCT04258553 Completed - Oxidative Stress Clinical Trials

Thiol Disulfide Balance in Cervix Cancer

Start date: September 1, 2018
Phase:
Study type: Observational

The aim of this research is to evaluate thiol‑disulfide balance in cervix cancer patients

NCT ID: NCT04256213 Active, not recruiting - Cervix Cancer Clinical Trials

COL Immunotherapy Before Radiochimio + Ipilimumab

COLIBRI
Start date: July 2, 2020
Phase: N/A
Study type: Interventional

This is a multicenter, single arm pilot study evaluating the biological impact of "Nivolumab + Ipilimumab" in patients with cervical squamous cell carcinoma requiring RT-CT as initial therapy

NCT ID: NCT04249856 Recruiting - Cervical Cancer Clinical Trials

Colposcopy and Dynamic Spectral Imaging (DSI)

Start date: February 1, 2017
Phase:
Study type: Observational

This study evaluates the Dynamic Spectral Imaging (DSI) Colposcope (DySIS) in it's ability to diagnose cervical dysplasia. Half of participants with be examined by the DySIS colposcope, there the other half will be examined by standard colposcopy.

NCT ID: NCT04096911 Recruiting - Cervical Cancer Clinical Trials

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Start date: July 31, 2019
Phase: Phase 2
Study type: Interventional

The investigators propose to evaluate the efficacy of the combination of Pd-1 Monoclonal Antibody and HPV Vaccine in the patients with cervical cancer who fails in or can not endure the standard treatment

NCT ID: NCT04072913 Completed - Cervix Cancer Clinical Trials

Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix

MMP-HPV
Start date: October 10, 2007
Phase: N/A
Study type: Interventional

This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.

NCT ID: NCT04067882 Recruiting - Cervix Cancer Clinical Trials

Validation of the Genetic Signature 354849 as a Prognostic Method

Start date: September 30, 2019
Phase:
Study type: Observational

This prospective study is focused on the validation of the genetic signature of 27 genes as a predictor of the response to concomitant chemotherapy treatment followed by brachytherapy in patients with locally advanced cervical cancer. The genes included are: ZNF238; SAP30; C10orf137; UHRF1; SUZ12; HMGN4; RBBP4; PPP1CB; SLFN11; FLJ39378; ENDOGL1; RECQL; TRPC1; TRIO; DNAH6; GNL3L; SLC36A2; SRP9; RPE; LDOC1L; PUS7L; CCDC89; LOC644921; PLEKHG1; FAM111B; RPRD2 y ETAA16.